LANGUAGE:
LANGUAGE:
Our people are our pride, helping companies resonate with their customers for 20+ years.
We create, transform, test, and train more content than anyone in the world – from text, voice, audio, video, to structured & unstructured data.
Solutions
Our experts know the in-and-outs of your industry & its challenges.
Harness the Lionbridge Lainguage Cloud to support your end-to-end localization and content lifecycle
Our people are our pride, helping companies resonate with their customers for 20+ years.
About Us
Key Facts
Leadership
Insights
News
Trust Center
We create, transform, test, and train more content than anyone in the world – from text, voice, audio, video, to structured & unstructured data.
Content Services
Technical Writing
Training & eLearning
Financial Reports
Multicultural Marketing
Digital Experience Assessments
Translation Services
Translation
Video Localization
Software Localization
Website Localization
Translation for Regulated Companies
Interpretation
Multilingual SEO & Digital Marketing
Content Optimization
Testing Services
Functional QA & Testing
Compatibility Testing
Interoperability Testing
Performance Testing
Accessibility Testing
UX/CX Testing
Solutions
Digital Marketing
Live Events
Machine Translation
Our Knowledge Hubs
Positive Patient Outcomes
Future of Localization
Innovation to Immunity
COVID-19 Resource Center
Disruption Series
Patient Engagement
Lionbridge Insights
Our experts know the in-and-outs of your industry & its challenges.
Life Sciences
Banking & Finance
Retail
E-Commerce
Games
Automotive
Consumer Packaged Goods
Technology
Industrial Manufacturing
Legal Services
Travel & Hospitality
Harness the Lionbridge Lainguage Cloud to support your end-to-end localization and content lifecycle
Lainguage Cloud™ Platform
Connectivity
Translation Community
Workflow Technology
Smairt Content™
Smairt MT™
Smairt Data™
Language Quality
Analytics
SELECT LANGUAGE:
This is the sixth piece in the Lionbridge Disruption Series, a collection of commentary from life sciences experts on how the industry is changing as a result of the COVID-19 crisis.
In March, the FDA released a policy for diagnostic tests for coronavirus to guide clinical laboratories, commercial manufacturers and FDA staff during the COVID-19 pandemic. Diagnostic tests for detection or diagnosis of the novel coronavirus (SARS-CoV-2) can be granted an Emergency Use Authorization (EUA) by the FDA.
This enables rapid development, manufacturing and distribution of tests under a public health emergency. Section 564 under the Federal Food, Drug and Cosmetic Act allows the use of unapproved medicinal drugs and devices under specific circumstances during emergencies such as the current pandemic.
Despite the extreme urgency of being able to detect and test for coronavirus, the validation of diagnostic assays remains important also under a pandemic such as COVID-19. A false negative result of a COVID-19 test can have consequences not only for the patient but also for public health in general. A patient who believes themselves not to be infected may unknowingly pass the virus on to dozens of others, magnifying the effect of an incorrect test. A false positive, on the other hand, can take precious hours away from contact trackers’ efforts as they try to retrace the patient’s step and determine whom to contact about exposure.
While test validation is not waived by the FDA, the policy does allow manufacturers to develop and distribute SARS-CoV-2 test kits before submission to the agency. (That submission is expected within 15 business days after validation of the test.) The submission of the EUA request to the FDA should include fact sheets for healthcare providers and patients, as well as instructions for use and proposed labeling/package inserts. Test kits that have received a Letter of Authorization under the EUA program will then be listed on the FDA webpage, along with both fact sheets and Instructions for Use.
Content intended for patients or healthcare professionals may require expedited translations for test kits being distributed internationally or to non-English speaking audiences. Lionbridge is uniquely positioned to support any global distribution of test kits because of our scale, our expertise in translating labeling and patient content for medical devices, and our industry-leading breadth of language solutions.
For more on our languages and regions of expertise, talk to someone on our team.